open access
Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis
open access
Abstract
Twelve patients, aged 6-29 were recruited. It was 20 week, placebo-controlled, and randomized, double blind, crossover trial. At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured. In montelukast group significantimprovementinFEV1(mean±SD,54,6 ± 22,6 before and 62 ± 19,0 after treatment, p = 0.0112) and FEF25/75% (28,9 ± 23,0 before and 37,5 ± 25,5 after treatment, p = 0.0053) were observed. Compared with placebo montelukast significantly improved FEV1(p = 0.0032),PEF(p = 0.0298)andFEF25/75%(p = 0.0091).There was no significant difference in VC, TGV, RawandRV. Montelukast compared with placebo significantlydecreasedcough(p < 0.0001)andwheezing(p = 0.0002)score. In summary, therapy with montelukast may provide clinical benefit to patients with CF.
Abstract
Twelve patients, aged 6-29 were recruited. It was 20 week, placebo-controlled, and randomized, double blind, crossover trial. At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured. In montelukast group significantimprovementinFEV1(mean±SD,54,6 ± 22,6 before and 62 ± 19,0 after treatment, p = 0.0112) and FEF25/75% (28,9 ± 23,0 before and 37,5 ± 25,5 after treatment, p = 0.0053) were observed. Compared with placebo montelukast significantly improved FEV1(p = 0.0032),PEF(p = 0.0298)andFEF25/75%(p = 0.0091).There was no significant difference in VC, TGV, RawandRV. Montelukast compared with placebo significantlydecreasedcough(p < 0.0001)andwheezing(p = 0.0002)score. In summary, therapy with montelukast may provide clinical benefit to patients with CF.
Keywords
cystic fibrosis; inflammation; leukotrienes; montelukast
About this articleTitle
Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis
Journal
Advances in Respiratory Medicine
Issue
Pages
85-89
Published online
2008-02-18
Bibliographic record
Pneumonol Alergol Pol 2004;72(3-4):85-89.
Keywords
cystic fibrosis
inflammation
leukotrienes
montelukast
Authors
Iwona Stelmach
Aleksandra Korzeniewska
Katarzyna Smejda
Iwona Jarosz
Włodzimierz Stelmach